company background image
BETA logo

Beta Drugs NSEI:BETA 株式レポート

最終価格

₹2.14k

時価総額

₹20.6b

7D

8.1%

1Y

82.1%

更新

28 Nov, 2024

データ

会社財務

Beta Drugs Limited

NSEI:BETA 株式レポート

時価総額:₹20.6b

BETA 株式概要

ベータ・ドラッグス社はインドで抗がん剤の開発、製造、販売を行っている。 詳細

BETA ファンダメンタル分析
スノーフレーク・スコア
評価0/6
将来の成長0/6
過去の実績3/6
財務の健全性6/6
配当金0/6

報酬

リスク分析


Beta Drugs Limited 競合他社

価格と性能

の歴代最高値、変動、値下がりまとめBeta Drugs
過去の株価
現在の株価₹2,143.45
52週高値₹2,326.00
52週安値₹1,060.05
ベータ0.58
11ヶ月の変化10.34%
3ヶ月変化26.60%
1年変化82.11%
33年間の変化316.20%
5年間の変化2,700.07%
IPOからの変化1,924.03%

最新ニュース

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Recent updates

Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Nov 08
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Aug 30
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Aug 30
Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%

Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Dec 23
Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%

Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

Dec 11
Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Jul 29
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Jun 17
Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching

Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Feb 21
Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Dec 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

Nov 21
With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting

These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Sep 02
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well

Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

May 20
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly

Is Beta Drugs (NSE:BETA) A Risky Investment?

Jan 29
Is Beta Drugs (NSE:BETA) A Risky Investment?

Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Dec 25
Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

Nov 20
Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)

株主還元

BETAIN PharmaceuticalsIN 市場
7D8.1%0.8%2.9%
1Y82.1%42.1%28.9%

業界別リターン: BETA過去 1 年間で42.1 % の収益を上げたIndian Pharmaceuticals業界を上回りました。

リターン対市場: BETA過去 1 年間で28.9 % の収益を上げたIndian市場を上回りました。

価格変動

Is BETA's price volatile compared to industry and market?
BETA volatility
BETA Average Weekly Movement8.4%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.0%

安定した株価: BETAの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: BETAの weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。

会社概要

設立従業員CEO(最高経営責任者ウェブサイト
2005371Rahul Batrabetadrugslimited.com

ベータ・ドラッグス社はインドで抗がん剤の開発、製造、販売を行っている。乳がん、肺がん、頭頸部がん、結腸直腸がん、卵巣がん、胃がん、精巣がん、腎がん、前立腺がん、脳腫瘍、白血病、リンパ腫、骨髄腫、支持体がん、皮膚がんなどのがん領域における製品を提供している。また、医薬品原薬の開発も行っている。製品の輸出も行っている。ベータ・ドラッグス・リミテッドは2005年に設立され、インドのパンチクラに拠点を置く。

Beta Drugs Limited 基礎のまとめ

Beta Drugs の収益と売上を時価総額と比較するとどうか。
BETA 基礎統計学
時価総額₹20.61b
収益(TTM)₹410.00m
売上高(TTM)₹3.35b

50.3x

PER(株価収益率

6.2x

P/Sレシオ

収益と収入

最新の決算報告書(TTM)に基づく主な収益性統計
BETA 損益計算書(TTM)
収益₹3.35b
売上原価₹2.01b
売上総利益₹1.34b
その他の費用₹925.54m
収益₹410.00m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益(EPS)42.65
グロス・マージン39.90%
純利益率12.25%
有利子負債/自己資本比率10.5%

BETA の長期的なパフォーマンスは?

過去の実績と比較を見る